In multivariate analysis, STK11ex1-2 mutations were strongly associated with a poor prognosis (P = .002), as well as advanced tumor stage (P < .001), age >70 years (P = .003), pneumonectomy (P = .03) and KRAS mutations (P = .01) (Table 2). This evidence concerns the gene KRAS and neoplasm.